Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Forms Drug Delivery and Patient Communication Partnership with 111

publication date: Mar 18, 2021

BeiGene, a Beijing oncology company, will collaborate with Shanghai's 111 Inc. to develop an Internet + Medicine & Healthcare model to support distribution of BeiGene's products. The companies will use 111's online platform to advertise BeiGene's drugs in China and deliver medications using its online and offline direct-to-patient (DTP) delivery service. They will also develop a patient management system to improve care, especially for patients outside of the hospital. At the moment, BeiGene has two novel approved products in China. More details....

Stock Symbols: (NSDQ: BGNE; HK:06160) (NSDQ: YI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.